Jim Wassil Sells 1,334 Shares of Vaxcyte (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) EVP Jim Wassil sold 1,334 shares of the firm’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $59.52, for a total transaction of $79,399.68. Following the completion of the sale, the executive vice president owned 145,435 shares in the company, valued at $8,656,291.20. The trade was a 0.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jim Wassil also recently made the following trade(s):

• On Friday, September 4th, Jim Wassil sold 1,381 shares of Vaxcyte stock. The shares were sold at an average price of $61.16, for a total value of $84,461.96.
• On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The stock was sold at an average price of $61.07, for a total value of $212,340.39.
• On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $53.86, for a total value of $121,185.00.
• On Wednesday, July 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $56.33, for a total value of $126,742.50.

Vaxcyte Price Performance

Shares of Vaxcyte stock opened at $58.90 on Friday. The business’s fifty day moving average price is $58.42 and its two-hundred day moving average price is $56.32. The company has a market capitalization of $8.76 billion, a P/E ratio of -7.72 and a beta of 1.22. Vaxcyte, Inc. has a 1-year low of $30.81 and a 1-year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.06) by $0.09. During the same period last year, the business posted ($1.22) EPS. On average, research analysts expect that Vaxcyte, Inc. will post -7.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vaxcyte

Several hedge funds have recently modified their holdings of the stock. Smartleaf Asset Management LLC boosted its position in shares of Vaxcyte by 156.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after purchasing an additional 364 shares during the period. Caitong International Asset Management Co. Ltd raised its holdings in Vaxcyte by 1,463.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after buying an additional 600 shares during the period. IFP Advisors Inc raised its holdings in Vaxcyte by 72.8% during the 2nd quarter. IFP Advisors Inc now owns 560 shares of the company’s stock worth $33,000 after buying an additional 236 shares during the period. EverSource Wealth Advisors LLC lifted its stake in Vaxcyte by 33.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after buying an additional 184 shares in the last quarter. Finally, CIBC Private Wealth Group LLC boosted its holdings in shares of Vaxcyte by 22,500.0% in the third quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock worth $49,000 after buying an additional 1,350 shares during the period. 96.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PCVX has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Wall Street Zen raised shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Zacks Research upgraded shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Vaxcyte has an average rating of “Moderate Buy” and a consensus price target of $86.00.

About Vaxcyte

Vaxcyte, Inc is a clinical-stage biotechnology company focused on developing vaccines to prevent serious bacterial infections. The company’s lead programs target pneumococcal disease, which can cause pneumonia, meningitis, bloodstream infections and other invasive illnesses. Vaxcyte is developing broad-spectrum pneumococcal conjugate vaccine candidates designed to protect against a wide range of bacterial serotypes.

Vaxcyte’s pipeline has included VAX-24, an investigational 24-valent pneumococcal conjugate vaccine, and VAX-31, a next-generation candidate designed to cover 31 serotypes.